<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03817645</url>
  </required_header>
  <id_info>
    <org_study_id>PCeo-17</org_study_id>
    <nct_id>NCT03817645</nct_id>
  </id_info>
  <brief_title>Panaceo &quot;MED&quot; for IBS (Irritable Bowel Syndrome)</brief_title>
  <acronym>PCeo-17</acronym>
  <official_title>Pilot-trial on the Use of the Panaceo Medicine Product &quot;MED&quot; for the Treatment of IBS (Irritable Bowel Syndrome)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scigenia GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scigenia GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Zeolite clinoptilolite is a volcanic mineral from the group of zeolites. The porous structure&#xD;
      is associated with a large inner surface. Due to the anionic framework charge, ions (e.g.,&#xD;
      Pb^2+) can be absorbed or exchanged. The specific Panaceo PMA zeolite is approved as a class&#xD;
      IIa medical device for the repair of the intestine inner lining. It is CE certified and&#xD;
      complies with the relevant European Union regulations in terms of safety and effectiveness.&#xD;
      Zeolite is known for its absorbing properties. Because of these properties and the results of&#xD;
      several human studies, it warrants the investigation of possible effects on specific&#xD;
      indications in human medicine, e.g. irritable bowel syndrome.&#xD;
&#xD;
      The diagnosis &quot;irritable bowel syndrome (IBS)&quot; is according to the ROME Foundation, an US&#xD;
      medical society. IBS is a disorder with dysfunction of the bowels, a latent inflammation is&#xD;
      discussed. The present study aims to evaluate the following effects in patients with IBS:&#xD;
&#xD;
        -  Primary endpoint: effect on the symptoms of IBS.&#xD;
&#xD;
        -  Secondary endpoint: intestinal wall permeability, integrity of the tight junctions as&#xD;
           measured by the change in zonulin concentration in the stool.&#xD;
&#xD;
        -  Further endpoints:&#xD;
&#xD;
             -  Inflammation parameters and anti-inflammatory laboratory parameters.&#xD;
&#xD;
             -  Biodiversity of the gastrointestinal microbiome.&#xD;
&#xD;
             -  histamine-associated parameters.&#xD;
&#xD;
             -  Constipation as a possible side effect.&#xD;
&#xD;
      For this purpose, a double-blind randomized controlled trial (RCT) is realized prospectively&#xD;
      in a monocentric outpatient-controlled study. The subjects take the test compound daily&#xD;
      (verum, reference substance) for 12 weeks and document the intake of the study-substance,&#xD;
      intake of medications, stool-frequency and consistency. They receive &quot;before&quot; and &quot;after&quot; the&#xD;
      intervention phase a blood and stool analysis for the determination of parameters for&#xD;
      intestinal wall integrity (zonulin) inflammation (hsCRP, interleukin-10, calprotectin),&#xD;
      histamine metabolism, microbiome diversity. The pilot study is realized ahead of the detailed&#xD;
      planning of a later main study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal discomfort or pain</measure>
    <time_frame>3 months</time_frame>
    <description>Frequency: 0 - never, 1 - less than once / month, 2 - once / month, 3 - two-three days / month, 4 - once per week, 5 - more than once per week, 6 - every day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom improvement with defaecation</measure>
    <time_frame>3 months</time_frame>
    <description>0 - never or rarely, 1 - sometimes, 2 - often, 3 - frequently, 4 - always.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool frequency associated with abdominal discomfort or pain (more or less frequent)</measure>
    <time_frame>3 months</time_frame>
    <description>0 - never or rarely, 1 - sometimes, 2 - often, 3 - frequently, 4 - always.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stool consistency associated with abdominal discomfort or pain (softer or harder)</measure>
    <time_frame>3 months</time_frame>
    <description>0 - never or rarely, 1 - sometimes, 2 - often, 3 - frequently, 4 - always.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool laboratory parameter: Firmicutes</measure>
    <time_frame>3 months</time_frame>
    <description>Genotyping of bacteria in stool, before and after intake of study substance; Prevalence Firmicutes (CFU/g stool)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool laboratory parameter: Bacteroidetes</measure>
    <time_frame>3 months</time_frame>
    <description>Genotyping of bacteria in stool, before and after intake of study substance; Prevalence Bacteroidetes (CFU/g stool)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool laboratory parameter: Ratio: Bacteroidetes/Firmicutes</measure>
    <time_frame>3 months</time_frame>
    <description>Genotyping of bacteria in stool, before and after intake of study substance; Computation of Ratio: Bacteroidetes/Firmicutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool laboratory parameter: Butyrat Producers</measure>
    <time_frame>3 months</time_frame>
    <description>Genotyping of bacteria in stool, before and after intake of study substance; Prevalence of Butyratproducing bacteria (CFU/g stool)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool laboratory parameter: Clostridia</measure>
    <time_frame>3 months</time_frame>
    <description>Genotyping of bacteria in stool, before and after intake of study substance; Prevalence of Clostridia (CFU/g stool)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool laboratory parameter: Histaminproducers,</measure>
    <time_frame>3 months</time_frame>
    <description>Genotyping of bacteria in stool, before and after intake of study substance; Prevalence of Histaminproducing bacteria (CFU/g stool)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool laboratory parameter: H2S producers</measure>
    <time_frame>3 months</time_frame>
    <description>Genotyping of bacteria in stool, before and after intake of study substance; Prevalence of H2S-producing bacteria (CFU/g stool)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of permeability (Leaky-Gut)</measure>
    <time_frame>3 months</time_frame>
    <description>Zonulin (&lt; 55 ng/ml) in stool</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of bowel inflammation</measure>
    <time_frame>3 months</time_frame>
    <description>Calprotectin (&lt; 50 mg/l) in stool</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of permeability of mucosa</measure>
    <time_frame>3 months</time_frame>
    <description>Alpha 1-Antitrypsin (&lt; 27,5 mg/dl) in stool</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of the inflammation mediator</measure>
    <time_frame>3 months</time_frame>
    <description>Histamin (&lt; 600 ng/ml) in stool</description>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy of binding and elimination of ammoniak</measure>
    <time_frame>3 months</time_frame>
    <description>Ammoniak (11-51 µmol/l) in blood / serum</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of inflammation</measure>
    <time_frame>3 months</time_frame>
    <description>high sensitivity C-reactive protein (mg/l) in blood / serum</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of anti-inflammatory mediator</measure>
    <time_frame>3 months</time_frame>
    <description>Interleukin-10 (&lt; 9,1 pg/ml) in blood / serum</description>
  </other_outcome>
  <other_outcome>
    <measure>Possible release of metal ions</measure>
    <time_frame>3 months</time_frame>
    <description>Aluminium (&lt; 11 µg/l) in blood / serum</description>
  </other_outcome>
  <other_outcome>
    <measure>Change of histamin metabolism</measure>
    <time_frame>3 months</time_frame>
    <description>Di-Amino-Oxydase (&gt; 10 U/ml) in blood / serum</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Microbial Colonization</condition>
  <condition>Intestinal Disease</condition>
  <arm_group>
    <arm_group_label>Panaceo MED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zeolite, Medicinal product, class IIa for oral intake, daily intake of 2 sachets (3 g), for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Micro crystalline cellulose daily intake of 2 sachets (3 g), for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Zeolite</intervention_name>
    <description>The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Panaceo MED</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Frequency of discomfort or pain in the abdomen in the last 3 months, more than 1 day&#xD;
             per week.&#xD;
&#xD;
          -  Start of the discomfort or pain more than 6 months ago.&#xD;
&#xD;
          -  Improvement of the discomfort or pain associated with bowel movements sometimes,&#xD;
             often, frequently, always.&#xD;
&#xD;
          -  Association of the discomfort or pain with a frequency change in bowel movements&#xD;
             sometimes, often, frequently, always.&#xD;
&#xD;
          -  Association of the discomfort or pain with a change in stool-consistency sometimes,&#xD;
             often, frequently, always.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age: younger than 18, older than 80.&#xD;
&#xD;
          -  Diagnosed inflammatory bowel disease (M. Crohn, Colitis Ulcerosa)&#xD;
&#xD;
          -  Diagnosed nutritional idiosyncrasy&#xD;
&#xD;
          -  Cancer treatment in the last 12 weeks&#xD;
&#xD;
          -  Depression in the last 12 weeks&#xD;
&#xD;
          -  Intake of weight loss supporting medication (Lipase inhibitors)&#xD;
&#xD;
          -  Alcohol, nicotine, drug-abuse&#xD;
&#xD;
          -  Status after organ-transplantation, intake of immunosuppressants&#xD;
&#xD;
          -  Acute or chronic neurologic or psychiatric disease&#xD;
&#xD;
          -  Acute or chronic heart disease or kidney disease&#xD;
&#xD;
          -  Acute or chronic liver damage or any other organ damages&#xD;
&#xD;
          -  Transient severe obstipation in the last 4 weeks&#xD;
&#xD;
          -  Transient acute diarrhea in the last 4 weeks (e.g. intestinal infection)&#xD;
&#xD;
          -  Intestinal cancer&#xD;
&#xD;
          -  Intake of Panaceo MED or other Zeolite in the last 4 weeks&#xD;
&#xD;
          -  Type I Diabetes or severe metabolic disease&#xD;
&#xD;
          -  Infection with fever in the last 4 weeks&#xD;
&#xD;
          -  Intake of cortisone or antibiotics in the last 4 weeks&#xD;
&#xD;
          -  Planed journey of more than 14 days in the next 12 weeks (change of nutritional&#xD;
             habits)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ventzislav Petkov, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SCIgenia GmbH</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Lamprecht M, Bogner S, Steinbauer K, Schuetz B, Greilberger JF, Leber B, Wagner B, Zinser E, Petek T, Wallner-Liebmann S, Oberwinkler T, Bachl N, Schippinger G. Effects of zeolite supplementation on parameters of intestinal barrier integrity, inflammation, redoxbiology and performance in aerobically trained subjects. J Int Soc Sports Nutr. 2015 Oct 20;12:40. doi: 10.1186/s12970-015-0101-z. eCollection 2015.</citation>
    <PMID>26500463</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zeolite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

